Increased ezrin expression has been associated with a poor prognosis in a variety of human cancers including osteosarcoma, soft tissue sarcomas (STS), breast, gastrointestinal, genitourinary, melanoma, astrocytoma, and squamous cell carcinoma of the head and neck [13–23]. Here, EZR is linked to osteosarcoma.